CX3CR1 and hepatocellular carcinoma: On the Monocyte panel, CX3CR1 on monocyte, CX3CR1 on CD14 + CD16 + monocyte and CX3CR1 on CD14 + CD16- monocyte could decrease the risk of HCC while CD40 on CD14 + CD16- monocyte could increase the risk of HCC.